Webinars and Commercial Conversations — Register Now

Tuesday, December 1, 2026, 1 PM-2 PM ET

Join UCSF clinical microbiologists as they share their journey from using multiple respiratory testing platforms to implementing a flexible, stewardship-driven testing strategy. Learn how customizable respiratory panels helped streamline workflows, improve efficiency, and better align testing with patient needs.

Webinar presenters Danielle Ingebrigtsen, MHS, Clinical Laboratory Scientist Supervisor, UCSF Health, and Rama Yakubu, MD, PhD, Assistant Professor of Laboratory Medicine, Co-Director of Microbiology, UCSF Health.

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diasorin.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, January 12, 2027, 2 PM-3 PM ET
Hear Dr. Roden discuss how computational pathology will impact the practice & future of precision oncology, using global real world analytical evidence for the novel TROP2 NMR biomarker as an example.

Webinar presenter Anja C. Roden, MD, Consultant, Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Professor of Laboratory Medicine and Pathology
Mayo Clinic College of Medicine and Science, Rochester, Minnesota

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Roche Diagnostics. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

2013 Issues

Q&A Column, 12/13

December 2013—Our hematology standardization committee has asked us for input on performing cell counts on tubes No. 1 and No. 4 for cerebrospinal fluid. Each site in our system has a different protocol set up with its emergency department with regard to when a count is performed on tube No. 1 after counting tube No. 4. Some sites use RBC greater than five to automatically count tube No. 1 with or without an order to not delay patient care, whereas other sites use greater than 50 or greater than 200. Is there an established guideline recommendation for the number of RBCs seen on CSF tube No. 4 before doing an additional count on tube No. 1?

Newsbytes, 12/13

December 2013—How software issues enhanced a vendor’s relationship with its client; Abbott releases new version of LIMS; Viewics introduces payer-focused solution; Syapse debuts clinical ‘omics’ reporting software; Telcor software receives certification as EHR module

Anatomic Pathology Selected Abstracts, 12/13

December 2013— Human papillomavirus-related carcinomas of the sinonasal tract; Localized and metastatic myxoid/round cell liposarcoma; Urothelial carcinoma with prominent squamous differentiation in neurogenic bladder: role of HPV infection; Atypical leiomyomas of the uterus: a clinicopathologic study of 51 cases; Clinicopathological significance of HER2/neu genetic heterogeneity in various breast carcinomas; EIN with secretory differentiation: features and underlying mechanisms; Glypican 3 and arginase in diagnosing scirrhous hepatocellular carcinoma

Put It on the Board, 12/13

December 2013—Illumina in November received premarket clearance from the FDA for the MiSeqDx system, the first high-throughput DNA sequencing analyzer to receive FDA clearance. Illumina also received FDA premarket clearance for the MiSeqDx Cystic Fibrosis 139-Variant Assay, MiSeqDx Cystic Fibrosis Clinical Sequencing Assay, and MiSeqDx Universal Kit.

Dropping the ball on critical value POC glucose results?

December 2013—Prompt reporting of critical laboratory results is considered an important patient safety goal. But for one of the most commonly performed tests, point-of-care glucose, there has been limited information about how critical results are handled. A new CAP Q-Probes study finds there is a great deal of variability. In addition to having widely differing critical result cutoff values, many laboratories are not repeating critical POC glucose test results for verification despite the relative high rate of erroneous results on first measurement.

Q&A Column, 11/13

November 2013—Can you explain the logic behind doing a full workup for identification and sensitivity on multiple positive blood culture bottles on the same patient, drawn on the same day?

Put It on the Board, 11/13

November 2013—Myriad Genetics presented last month new clinical data from a study with myRisk Hereditary Cancer, a 25-gene hereditary cancer panel, that showed a 60 percent increase in mutations detected in cancer predisposition genes in patients with a prior history of colon cancer, polyps, or both. Myriad presented this study and data from four others at the Collaborative Group of the Americas on Inherited Colorectal Cancer Annual Meeting in Anaheim, Calif.

Clinical pathology selected abstracts

November 2013—Analysis of transfusion related lung injury in children; Assessing outcomes of medical emergencies on commercial airline flights; Link between inflammatory biomarkers and risk of exacerbations in COPD

Anatomic Pathology Selected Abstracts, 11/13

November 2013—Diagnostic and prognostic morphometric features in WHO 2003 invasive endometrial stromal tumors; Association of tumor staging with adverse clinical outcome in neuroendocrine tumors of appendix; Detection of HPV capsid proteins L1 and L2 in squamous intraepithelial lesions; Feasibility and safety of sequential research-related tumor core biopsies in clinical trials; Evaluation of breast amyloidosis finds AL type most prevalent; Outside case review of surgical pathology for referred patients: impact on patient care; Reporting trends for right-sided hyperplastic and sessile serrated polyps; Atypical leiomyomas of the uterus: a clinicopathologic study of 51 cases; Pathological diagnostic criterion of blood and lymphatic vessel invasion in colorectal cancer

Newsbytes, 11/13

November 2013—New connectivity standards nearly ready to roll; CAP and mTuitive create application for care of cancer patients; European firm purchases Centricity LIS from GE; NovoPath offers Citrix platform for AP system; AHRQ tool focuses on lab test processes in medical offices; Brazilian hospital selects Cerner system